Related Experiment Video
Updated: Oct 1, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Antitumor effects of Flt3 ligand in transplanted murine tumor models
Bruce J Averbook1, Joann L Schuh, Robert Papay
1Department of Surgery, MetroHealth Medical Center/Case Western Reserve University, Cleveland, Ohio, USA. baverbook@mhmc.org
Abstract:
Administration of Flt3 ligand (FL) to mice causes dendritic and natural killer cells to increase but certain solid tumors to regress. Depending on the particular tumor model used, T cells and natural killer cells have been implicated in the protective immune response induced by FL. The current study examined the effects of FL administration on tumor establishment and progression in metastatic and primary tumor models to correlate anatomic location with immunotherapeutic efficacy. FL mediated significant (p < or = 0.05) therapeutic activity against pulmonary metastases of the murine MC-38 colon adenocarcinoma, particularly when cytokine administration was initiated before tumor inoculation. However, progressive intraabdominal tumors sometimes were observed even in the relative absence of pulmonary metastases. Significant, although less dramatic, antimetastatic effects were observed with MCA-205 and MCA-102 sarcomas and D5 (B16BL6) melanoma. In contrast, FL was ineffective against subcutaneous MC-38 tumors or against several intracranial tumors. This suggests that besides the administration dose, the efficacy of this cytokine depends on the tumor type and possibly the location of the inoculated tumor. Antitumor activities of FL were abolished by whole-body irradiation (500 cGy) and partially abolished by systemic depletion of CD8, CD4, or natural killer cells. The results indicate that optimization of FL immunotherapy of tumors will require a firmer understanding of the relative contributions of tumor burden, location, immune system requirements, and other factors.
Insights
Flt3 ligand (FL) immunotherapy shows efficacy against metastatic tumors in mice, particularly lung metastases. However, its effectiveness varies by tumor type and location, indicating a need for further research into optimizing its use.
Area of Science:
- Immunology
- Cancer Research
- Pharmacology
Background:
- Flt3 ligand (FL) administration in mice increases dendritic and natural killer cells, leading to regression of certain solid tumors.
- T cells and natural killer cells are implicated in the immune response induced by FL, depending on the tumor model.
- The study investigates the correlation between anatomic location and immunotherapeutic efficacy of FL.
Purpose of the Study:
- To examine the effects of FL administration on tumor establishment and progression in metastatic and primary tumor models.
- To correlate anatomic location with immunotherapeutic efficacy of FL.
- To understand the factors influencing FL's efficacy in cancer treatment.
Main Methods:
- Administration of Flt3 ligand (FL) to mice with various tumor models (MC-38 colon adenocarcinoma, MCA-205, MCA-102 sarcomas, D5 melanoma).
- Evaluation of therapeutic activity against pulmonary metastases, intraabdominal tumors, subcutaneous tumors, and intracranial tumors.
- Assessment of FL efficacy following whole-body irradiation and systemic depletion of CD8, CD4, or natural killer cells.
Main Results:
- FL demonstrated significant therapeutic activity against pulmonary metastases of MC-38 colon adenocarcinoma, especially when administered before tumor inoculation.
- Progressive intraabdominal tumors were observed despite FL treatment, even with limited pulmonary metastases.
- Significant antimetastatic effects were noted for MCA-205, MCA-102 sarcomas, and D5 melanoma, but FL was ineffective against subcutaneous MC-38 tumors and intracranial tumors.
- Antitumor activities of FL were abolished by irradiation and partially abolished by depletion of CD8, CD4, or NK cells.
Conclusions:
- The efficacy of Flt3 ligand (FL) immunotherapy is dependent on tumor type and location, in addition to dosage.
- FL shows potential as an antimetastatic agent, particularly against lung metastases.
- Optimization of FL immunotherapy requires a deeper understanding of tumor burden, location, and immune system requirements.
